CD158i _ KIR2DS4 Control Peptide antibody Ab_CP
- Known as:
- CD158i _ KIR2DS4 Control Peptide (anti-) Ab_CP
- Catalog number:
- AP18084CP-N
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- CD158i _ KIR2DS4 Control Peptide antibody Ab_CP
Related genes to: CD158i _ KIR2DS4 Control Peptide antibody Ab_CP
- Gene:
- KIR2DS4 NIH gene
- Name:
- killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 4
- Previous symbol:
- -
- Synonyms:
- cl-39, KKA3, nkat8, CD158i
- Chromosome:
- 19q13.42
- Locus Type:
- gene with protein product
- Date approved:
- 1997-11-14
- Date modifiied:
- 2016-01-20
Related products to: CD158i _ KIR2DS4 Control Peptide antibody Ab_CP
Related articles to: CD158i _ KIR2DS4 Control Peptide antibody Ab_CP
- Haplo-identical hematopoietic cell transplantation (haploHCT) is an integral treatment paradigm for patients with leukemia. While overall survival (OS) post-haploHCT has steadily improved, relapse-free survival (RFS) remains relatively stagnant. Upon the discovery of killer immunoglobulin-like receptors (KIRs) on natural killer (NK) cells and their cognate human leukocyte antigen (HLA) ligands, algorithms have been developed to enhance graft versus leukemia effects. However, these algorithms fail to yield consistent predictions in patient outcomes. We utilized a combination of protein folding and interactions to determine KIR:HLA reactivity in conjunction with acoustic force microscopy to measure cell avidity (CA) as a readout for KIR signal strength. CA was determined using monoallelic HLA expressing K562 cell lines, monoallelic KIR Jurkat cells, and peripheral blood NK cells. We extended the CA results and performed standard cytotoxicity assays as well. We discovered that HLA-B*35 interacts with KIR2DS4. We applied the newly discovered interaction to predict outcomes for HCT patients. Stratifying patients based on their HLA-B*35 positivity and donor KIR2DS4 status, we delineated a correlation to survival (P=0.061) when donors only had full-length KIR2DS4. Patients who received a haploHCT and NK cell addback from donors with only full-length KIR2DS4 had a significantly improved RFS (P=0.001) and OS (P=0.016) compared to truncated (KIR1D) and full-length KIR2DS4 donors. This was independently validated in a diverse 10/10 HLA matched European cohort with RFS (P=0.0255) and OS (P=0.0388). Thus, the identified novel KIR2DS4:HLA-B*35 interaction axis predicts patient survival, in both haplo-identical and fully matched, HCT and highlights that our current understanding of the KIR:HLA interactome is incomplete and requires remapping for enhanced therapeutic applications. - Source: PubMed
Publication date: 2026/08/06
Gottschalk StephenLi YingSelukar SubodhKirk Alison MNaik SwatiFürst DanielMannes SophieFlossdorf SarahBeyersmann JanSchezenmeier HubertFranke Georg-Nikolaus Thomas Paul GTriplett Brandon MChockley Peter J - The killer-cell immunoglobulin-like receptors (KIR) are a family of activating and inhibitory Class I human leukocyte antigen (HLA-I) binding receptors expressed on natural killer (NK) cells and subsets of T cells. The KIR detect HLA-I molecules in a peptide-dependent manner, with some KIR displaying exquisite peptide specificity. Studying peptide recognition by KIR often uses TAP-deficient cell lines expressing single HLA-I alleles, which are heterogenous and time consuming to generate. Here, we established an alternative approach using peptide-exchange technologies hitherto developed for studying T cell recognition of HLA-I. - Source: PubMed
Publication date: 2026/05/25
Murali Tanusya MLi BeiningHoos EmeryCollinson LucyLong Eric ODushek OmerElliott TimSim Malcolm J W - To identify druggable genes associated with cataract and investigate their functional roles under oxidative stress, thereby providing potential therapeutic targets. - Source: PubMed
Publication date: 2026/04/16
Lin MinZeng Jie - Although IFI44 is recognized for its crucial role in autoimmune disorders, its function in breast cancer (BC) remains unclear. This study aimed to investigate the immune-related and prognostic significance of IFI44 in BC. - Source: PubMed
Publication date: 2026/04/08
Wu JiahuiYi WangLiu MengtingLi YingliangZhou BoxuanWu ZiyunCao WeiShi QingfengCai XiangkaiXiong Haiwei - The killer-cell immunoglobulin-like receptor () gene cluster exhibits complicated diversity in haplotype content, copy-number variation (CNV), and allelic polymorphism. To date, 2,286 distinct alleles have been released in the IPD-KIR Database. However, little is known about the impact of high-resolution-level allelic polymorphisms on leukemia. Our previous study showed that the genotype carrying more inhibitory genes conferred differential protection against leukemia in the Chinese Southern Han population. Herein, we hypothesized the impact of alleles in the haplotype and cognate human leukocyte antigen (HLA) ligand on leukemia. - Source: PubMed
Publication date: 2026/02/05
Deng ZhihuiZhen JianxinLi YunanLiang ShuangZhang ManruCai SiqiJiang RenhuiYang ZhichaoYu QiongWang JinyongLiu Jie